JNGLX: Janus Henderson Global Life Sciences D

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Fixed income news, reports, video and more.

Municipal bonds news, reports, video and more.

Practice management news, reports, video and more.

Portfolio management news, reports, video and more.

Retirement news, reports, video and more.

Learn from industry thought leaders and expert market participants.

Deepen your understanding of Responsible Investing and learn how it can potentially help you build a more successful practice.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

JNGLX Janus Henderson Global Life Sciences D


Profile

JNGLX - Profile

Vitals

  • YTD Return 9.5%
  • 3 Yr Annualized Return 6.2%
  • 5 Yr Annualized Return 2.9%
  • Net Assets $4.43 B
  • Holdings in Top 10 30.9%

52 WEEK LOW AND HIGH

$67.15
$45.67
$68.58

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.82%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 36.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

Closed to new investors as of Feb 12, 2010
  • Standard (Taxable) $2,500
  • IRA N/A

Fund Classification


Distributions

  • YTD Total Return 9.5%
  • 3 Yr Annualized Total Return 6.6%
  • 5 Yr Annualized Total Return 5.1%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.48%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Semi-Annually

Fund Details

  • Legal Name
    Janus Henderson Global Life Sciences Fund
  • Fund Family Name
    Janus Henderson
  • Inception Date
    Dec 31, 1998
  • Shares Outstanding
    N/A
  • Share Class
    D
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Andrew Acker

Fund Description

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.


Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.


Categories

Fund Company Quick Screens

JNGLX - Fund Company Quick Screens


Performance

JNGLX - Performance

Return Ranking - Trailing

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
YTD 9.5% -12.0% 23.1% 30.23%
1 Yr 19.6% 0.0% 42.1% 43.65%
3 Yr 6.2%* -13.6% 17.6% 38.18%
5 Yr 2.9%* -11.1% 13.5% 30.10%
10 Yr 11.6%* -2.1% 16.5% 16.67%

* Annualized

Return Ranking - Calendar

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
2019 21.5% 5.7% 55.4% 40.52%
2018 -7.9% -25.3% 21.5% 57.27%
2017 21.1% -10.8% 43.9% 29.63%
2016 -13.4% -31.6% 6.9% 39.05%
2015 -0.8% -20.4% 13.8% 33.00%

Total Return Ranking - Trailing

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
YTD 9.5% -12.0% 23.1% 30.23%
1 Yr 19.6% 0.0% 42.1% 43.65%
3 Yr 6.6%* -13.6% 20.6% 47.27%
5 Yr 5.1%* -11.1% 18.3% 40.78%
10 Yr 15.4%* -2.1% 18.7% 22.62%

* Annualized

Total Return Ranking - Calendar

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
2019 21.5% 5.7% 55.4% 40.52%
2018 -7.9% -25.3% 22.2% 63.64%
2017 22.6% -10.8% 45.8% 29.63%
2016 -13.1% -24.2% 8.7% 55.24%
2015 8.2% -16.6% 15.2% 30.00%

NAV & Total Return History


Holdings

JNGLX - Holdings

Concentration Analysis

JNGLX Category Low Category High JNGLX % Rank
Net Assets 4.43 B 2.42 M 49.6 B 14.81%
Number of Holdings 101 27 433 34.81%
Net Assets in Top 10 1.29 B 784 K 18.8 B 18.52%
Weighting of Top 10 30.85% 23.7% 75.9% 91.11%

Top 10 Holdings

  1. Merck & Co Inc 3.70%
  2. Novartis AG ADR 3.64%
  3. UnitedHealth Group Inc 3.56%
  4. AbbVie Inc 3.44%
  5. Roche Holding AG Dividend Right Cert. 3.03%
  6. Thermo Fisher Scientific Inc 2.95%
  7. AstraZeneca PLC 2.93%
  8. Abbott Laboratories 2.63%
  9. Humana Inc 2.58%
  10. Boston Scientific Corp 2.40%

Asset Allocation

Weighting Return Low Return High JNGLX % Rank
Stocks
95.55% 61.47% 100.23% 80.00%
Other
3.47% -3.74% 6.07% 2.96%
Cash
0.99% -0.23% 32.46% 65.19%
Preferred Stocks
0.00% 0.00% 6.63% 45.19%
Convertible Bonds
0.00% 0.00% 0.00% 30.37%
Bonds
0.00% 0.00% 0.06% 33.33%

Stock Sector Breakdown

Weighting Return Low Return High JNGLX % Rank
Healthcare
100.00% 73.33% 100.00% 12.59%
Utilities
0.00% 0.00% 0.00% 30.37%
Technology
0.00% 0.00% 20.28% 39.26%
Real Estate
0.00% 0.00% 2.13% 35.56%
Industrials
0.00% 0.00% 6.39% 33.33%
Financial Services
0.00% 0.00% 2.43% 61.48%
Energy
0.00% 0.00% 0.00% 30.37%
Communication Services
0.00% 0.00% 3.18% 33.33%
Consumer Defense
0.00% 0.00% 1.05% 37.04%
Consumer Cyclical
0.00% 0.00% 1.12% 36.30%
Basic Materials
0.00% 0.00% 2.61% 49.63%

Stock Geographic Breakdown

Weighting Return Low Return High JNGLX % Rank
US
74.76% 47.91% 99.43% 71.85%
Non US
20.79% 0.00% 43.93% 37.04%

Expenses

JNGLX - Expenses

Operational Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.82% 0.10% 25.14% 81.82%
Management Fee 0.64% 0.00% 1.25% 38.52%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.12% 0.03% 0.40% 34.88%

Sales Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% 4.88%

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 36.00% 0.70% 248.00% 46.56%

Distributions

JNGLX - Distributions

Dividend Yield Analysis

JNGLX Category Low Category High JNGLX % Rank
Dividend Yield 0.00% 0.00% 0.05% 32.59%

Dividend Distribution Analysis

JNGLX Category Low Category High Category Mod
Dividend Distribution Frequency Semi-Annually Annually Annually Annually

Net Income Ratio Analysis

JNGLX Category Low Category High JNGLX % Rank
Net Income Ratio 0.48% -2.53% 2.12% 14.29%

Capital Gain Distribution Analysis

JNGLX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

JNGLX - Fund Manager Analysis

Managers

Andrew Acker


Start Date

Tenure

Tenure Rank

May 01, 2007

13.35

13.4%

Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.01 22.98 8.6 20.35